CX-4945

DRUG4 trials

Sponsors

Cylene Pharmaceuticals, Senhwa Biosciences, Inc.

Conditions

COVID-19Carcinoma, Basal CellCholangiocarcinomaMultiple Myeloma

Phase 1

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Cylene PharmaceuticalsMultiple Myeloma

Start: 2010-09-30End: 2011-09-30Target: 22Updated: 2011-06-15

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

CompletedNCT02128282

Senhwa Biosciences, Inc.Cholangiocarcinoma

Start: 2014-06-30End: 2021-08-05Updated: 2021-10-22

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

CompletedNCT03897036

Senhwa Biosciences, Inc.Carcinoma, Basal Cell

Start: 2019-04-16End: 2024-01-25Updated: 2025-05-20

A Study of Silmitasertib (CX-4945) in Healthy Subject

CompletedNCT05817708

Senhwa Biosciences, Inc.COVID-19

Start: 2022-11-28End: 2023-06-20Updated: 2025-01-27

Related Papers

Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.

Journal of Clinical Oncology2021-01-2026 citations

A phase I study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma.

Journal of Clinical Oncology2020-05-203 citations

A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma.

Journal of Clinical Oncology2017-02-014 citations